Related Experiment Video
Updated: Mar 28, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Systematic Review and Meta-Analysis: Macrolides- and Amoxicillin/Clavulanate-induced Acute Liver Injury
Pili Ferrer1, Justyna Amelio2, Elena Ballarín1,3,4
1Foundation Catalan Institute of Pharmacology, Barcelona, Spain.
Abstract:
Antibacterials are frequently associated with idiosyncratic drug-induced liver injury (DILI). The objective of this study was to estimate the risk of macrolides and amoxicillin/clavulanate (AMC) on DILI. We conducted a systematic review (SR) and meta-analysis (MA) with studies retrieved from PubMed, Cochrane Library Plus, Web of Knowledge, clinicaltrials.gov, Livertox and Toxline (1980-2014). We searched for macrolides, AMC and MeSH and synonym terms for DILI. We included all study designs except case reports/series, all population ages and studies with a placebo/non-user comparator. We summarized the evidence with a random-effects MA. Quality of the studies was appraised with a checklist developed for SR of adverse effects. Heterogeneity and publication bias were assessed with different exploratory tools. We finally included 10 (two randomized clinical trials, six case-control, one cohort and one case-population studies) and 9 (case-population excluded) articles in the SR and MA, respectively. The overall summary relative risk of DILI for macrolides was 2.85 [95% confidence interval (CI) 1.81-4.47], p < 0.0001, I(2) = 57%. Three studies were perceived to be missing in the area of low statistical significance. Year of study and selected exposure window partly explained the variability between studies. For AMC, the risk of DILI was 9.38 (95% CI 0.65-135.41) p = 0.3, I2 = 95%. In conclusion, although spontaneous reports and case series have long established an association between macrolides and AMC with acute liver injury, these SR and MA have assessed the magnitude of this association. The low incidence of DILI and the therapeutic place of these antibiotics might tilt the balance in favour of their benefits.
Insights
Macrolide antibiotics significantly increase the risk of drug-induced liver injury (DILI). Amoxicillin/clavulanate (AMC) also showed a higher DILI risk, though not statistically significant in this meta-analysis.
Area of Science:
- Pharmacovigilance
- Hepatology
- Drug Safety
Background:
- Idiosyncratic drug-induced liver injury (DILI) is a known risk associated with antibacterial agents.
- Macrolides and amoxicillin/clavulanate (AMC) are commonly prescribed antibacterials requiring risk assessment for DILI.
Purpose of the Study:
- To systematically review and meta-analyze the risk of DILI associated with macrolides and amoxicillin/clavulanate (AMC).
Main Methods:
- A systematic review and random-effects meta-analysis of studies published between 1980-2014.
- Searched databases including PubMed, Cochrane Library Plus, Web of Knowledge, clinicaltrials.gov, Livertox, and Toxline.
- Included studies of all designs (except case reports/series) with placebo or non-user comparators.
Main Results:
- Macrolides were associated with a summary relative risk of DILI of 2.85 (95% CI 1.81-4.47, p < 0.0001).
- Amoxicillin/clavulanate (AMC) showed a summary relative risk of DILI of 9.38 (95% CI 0.65-135.41, p = 0.3), with high heterogeneity (I² = 95%).
Conclusions:
- This meta-analysis quantifies the association between macrolides and AMC with acute liver injury.
- Despite identified risks, the low incidence of DILI and the therapeutic importance of these antibiotics suggest their benefits may outweigh risks.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Drug Toxicity: Risk factors
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

